Xoma Royalty-backed XRA 5 completed the acquisition of Mural Oncology for $36.2m.

Xoma Royalty-backed XRA 5, a newly established Delaware corporation, completed the acquisition of Mural Oncology, a clinical-stage immuno-oncology company, for $36.2m. "The Transaction Agreement with XOMA Royalty announced today is the result of a thorough and wide-ranging strategic review process, conducted with the support of our legal and financial advisors. We believe that this transaction, which is supported by our Board, achieves the goal of this strategic review process, which was to maximize shareholder value," Caroline Loew, Mural Oncology CEO.